Following the FDA clearance of its Versius robot last fall, CMR Surgical has posted another major funding round, raising more than $200 million to bolster its U.S. commercial launch.
The financing tallied up a combination of equity and debt, with the latter including a new investment from Trinity Capital. The Cambridge, U.K.-based company also said that all of its previous major backers returned to join the round—a group that’s counted Softbank, Ally Bridge Group and Tencent, among others.
The proceeds will also support Versius’ international reach in soft-tissue surgeries, as well as the continued development of the upgraded Versius Plus system, currently only available in Europe and the U.K.
“We are now at a pivotal stage, poised to capitalise on significant opportunities for market expansion, including in the U.S., while continuing to penetrate deeper into existing markets,” CEO Massimiliano Colella said in a statement.
According to the former Fierce 15 winner, Versius’ cart-based, laparoscopic approach has so far been used in more than 30,000 procedures worldwide, across colorectal, gynecologic, thoracic, urologic and general surgeries. The company said that more than 70% of the hospitals that have adopted Versius are employing it within two or more medical specialties.
The multi-port system previously received a CE Mark in Europe in early 2019, and in October 2024 the FDA cleared it for minimally invasive gallbladder removals.
Last fall also saw CMR’s previous CEO, Supratim Bose, step down for personal reasons. Colella, formerly the company’s chief commercial officer, was named interim CEO before being formally appointed to the post in January.
Versius Plus, meanwhile, carries CE-marked tech including vLimeLite—near-infrared, fluorescent light that reacts with an injectable medical dye to highlight blood vessels and tissue perfusion—and an ultrasonic dissector as its first advanced energy instrument. It also supports the Versius Clinical Insights digital data platform.
CMR previously raised $165 million in late 2023, after securing a massive $600 million series D round in mid-2021.